[Treatment of acute intermittent porphyria with a new protein-bound lyophilized hematin].
Hematin (iron-III-protoporphyrin 9) has been used for several years in the treatment of acute attacks of inducible porphyrias. Three patients were treated with a new, albumin-bound lyophilized hematin preparation (manufactured by Behringwerke). In all patients it achieved a reduction in the urine of the porphyrin precursors porphobilinogen and 5-aminolevulin acid. In two patients the clinical symptoms were clearly improved, while a third patient died with tetraparesis. Hematin administration proved superior to the preceding glucose treatment. No abnormality of clotting or thrombophlebitis was detectable after hematin infusion.
D000208:Acute Disease; D000328:Adult; D005260:Female; D005612:Freeze Drying; D006418:Heme / Q000031:analogs & derivatives*; D006427:Hemin / Q000627:therapeutic use*; D006801:Humans; D011162:Porphobilinogen / Q000097:blood; D011164:Porphyrias / Q000097:blood / Q000188:drug therapy*; D011485:Protein Binding
D006418:Heme; D006427:Hemin; D011162:Porphobilinogen
Behandlung der akut intermittierenden Porphyrie mit einem neuen, an Albumin gebundenen lyophilisierten Hämatin.